{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:49:13Z","timestamp":1791582553010,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.coi.2026.102774","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:16:17Z","timestamp":1776125777000},"page":"102774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["New developments and future directions in the management of systemic lupus erythematosus"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-0065","authenticated-orcid":false,"given":"Kyriakos A","family":"Kirou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael A","family":"Kirou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Flouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2026.102774_bib1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-016-0562-3","article-title":"What causes lupus flares?","volume":"18","author":"Fernandez","year":"2016","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.coi.2026.102774_bib3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev-pathol-020117-043952","article-title":"Type I interferons in autoimmune disease","volume":"14","author":"Crow","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.coi.2026.102774_bib4","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1136\/ard-2022-223741","article-title":"Pathogenesis of systemic lupus erythematosus: risks, mechanisms and therapeutic targets","volume":"82","author":"Crow","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2026.102774_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.ady0210","article-title":"Epstein-Barr virus reprograms autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus","volume":"17","author":"Younis","year":"2025","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2026.102774_bib7","doi-asserted-by":"crossref","first-page":"R35","DOI":"10.1093\/hmg\/ddaf066","article-title":"Recent insights into the role of innate immunity in lupus","volume":"34","author":"Robinson","year":"2025","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.coi.2026.102774_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coi.2026.102774_bib9","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1002\/art.20798","article-title":"Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus","volume":"50","author":"Kirou","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102774_bib10","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.immuni.2024.09.004","article-title":"Type I IFN drives unconventional IL-1\u03b2 secretion in lupus monocytes","volume":"57","author":"Caielli","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2026.102774_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib12","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130062","article-title":"PD-1hiCXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21","volume":"4","author":"Bocharnikov","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2026.102774_bib13","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.immuni.2018.08.015","article-title":"Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus","volume":"49","author":"Jenks","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2026.102774_bib14","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-025-01291-0","article-title":"Immune-cell profiling to guide stratification and treatment of patients with rheumatic diseases","volume":"21","author":"Rao","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI181034","article-title":"Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis","volume":"135","author":"Horisberger","year":"2025","journal-title":"J Clin Invest"},{"key":"10.1016\/j.coi.2026.102774_sbref16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41584-025-01318-6","article-title":"Cutaneous lupus erythematosus - from pathogenesis to targeted therapy","volume":"21","author":"Klein","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib17","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2026.102774_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.860726","article-title":"Molecular taxonomy of systemic lupus erythematosus through data-driven patient stratification: molecular endotypes and cluster-tailored drugs","volume":"13","author":"Garantziotis","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102774_bib19","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/j.ekir.2024.03.014","article-title":"Interferon and B-cell signatures inform precision medicine in lupus nephritis","volume":"9","author":"Parodis","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.coi.2026.102774_bib20","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001526","article-title":"Validation of eight endotypes of lupus based on whole-blood RNA profiles","volume":"12","author":"Hubbard","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102774_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1136\/ard-2024-225664","article-title":"Disentangling the riddle of systemic lupus erythematosus with antiphospholipid syndrome: blood transcriptome analysis reveals a less-pronounced IFN-signature and distinct molecular profiles in venous versus arterial events","volume":"83","author":"Nikolopoulos","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_sbref22","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/art.42652","article-title":"Obexelimab in systemic lupus erythematosus with exploration of response based on gene pathway co-expression patterns: a double-blind, randomized, placebo-controlled, phase 2 trial","volume":"75","author":"Merrill","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib23","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/art.21031","article-title":"Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease","volume":"52","author":"Kirou","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102774_bib24","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.138345","article-title":"Integrated urine proteomics and renal single-cell genomics identify an IFN-\u03b3 response gradient in lupus nephritis","volume":"5","author":"Fava","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.coi.2026.102774_bib25","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.43212","article-title":"2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis","volume":"77","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib26","article-title":"2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus","author":"Sammaritano","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update","volume":"85","author":"Fanouriakis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.980079","article-title":"Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment","volume":"13","author":"Kirou","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102774_bib29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib30","doi-asserted-by":"crossref","unstructured":"Manzi S, Bruce IN, Morand EF, et al.: Efficacy and safety of subcutaneous anifrolumab in systemic lupus erythematosus: A Randomized, Phase 3 Study. Arthritis Rheumatol. Published online December 29, 2025. https:\/\/doi.org\/10.1002\/art.70041","DOI":"10.1002\/art.70041"},{"key":"10.1016\/j.coi.2026.102774_sbref31","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-000910","article-title":"Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial","volume":"10","author":"Jayne","year":"2023","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102774_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2025-001705","article-title":"Enpatoran, a first-in-class, selective, orally administered Toll-like receptor 7\/8 inhibitor, in systemic and cutaneous lupus erythematosus: results from a randomised, placebo-controlled phase Ib study","volume":"12","author":"Witte","year":"2025","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102774_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.70059","article-title":"Safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of afimetoran, a Toll-like receptor 7 and 8 inhibitor, in patients with cutaneous lupus erythematosus: a phase 1b randomized, double-blind, placebo-controlled study","volume":"7","author":"Hosein","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004701","article-title":"Safety, pharmacokinetics, biomarker response and efficacy of E6742: a dual antagonist of Toll-like receptors 7 and 8, in a first in patient, randomised, double-blind, phase I\/II study in systemic lupus erythematosus","volume":"10","author":"Tanaka","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102774_sbref35","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib36","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0140-6736(22)02607-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I)","volume":"401","author":"Morand","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102774_bib37","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2026.102774_sbref38","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_sbref39","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib40","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3390\/cancers12041045","article-title":"Transmembrane activator and CAML interactor (TACI): another potential target for immunotherapy of multiple myeloma?","volume":"12","author":"Xu","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.coi.2026.102774_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000412","article-title":"Comparative analysis of long-term organ damage in patients with systemic lupus erythematosus using belimumab versus standard therapy: a post hoc longitudinal study","volume":"7","author":"Urowitz","year":"2020","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102774_sbref42","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","article-title":"A phase 3 trial of telitacicept for systemic lupus erythematosus","volume":"393","author":"van Vollenhoven","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_sbref43","first-page":"410","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis. Reply","volume":"393","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib44","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ard.2025.11.015","article-title":"B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment","volume":"85","author":"Agmon-Levin","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib45","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1177\/09612033241260283","article-title":"Sustained depression of B cell counts in lupus nephritis after treatment with rituximab and\/or belimumab is associated with fewer disease flares","volume":"33","author":"Zisa","year":"2024","journal-title":"Lupus"},{"key":"10.1016\/j.coi.2026.102774_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2025.152786","article-title":"CAR T-cell therapy in SLE: a systematic review","volume":"74","author":"Nordmann-Gomes","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.coi.2026.102774_bib47","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMra2312718","article-title":"Neonatal Fc receptor - biology and therapeutics","volume":"392","author":"Bussel","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/ITT.S485650","article-title":"Immunotargets and therapy for systemic lupus erythematosus","volume":"14","author":"Mok","year":"2025","journal-title":"Immunotargets Ther"},{"key":"10.1016\/j.coi.2026.102774_bib49","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001112","article-title":"Mezagitamab in systemic lupus erythematosus: clinical and mechanistic findings of CD38 inhibition in an autoimmune disease","volume":"11","author":"McDonnell","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.coi.2026.102774_bib50","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/s41392-025-02487-2","article-title":"Anti-CD38 monoclonal antibody CM313 for systemic lupus erythematosus: a randomized, double-blind, placebo-controlled phase Ib\/IIa trial","volume":"10","author":"Zhao","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.coi.2026.102774_bib51","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.imbio.2025.152915","article-title":"Systemic lupus erythematosus as the paradigm for understanding the complex immune relationships and therapeutic opportunities for targeting complement in autoimmune diseases","volume":"230","author":"Holers","year":"2025","journal-title":"Immunobiology"},{"key":"10.1016\/j.coi.2026.102774_bib53","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102774_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-005557","article-title":"Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: a randomised, double-blind, placebo-controlled, phase II study","volume":"11","author":"Shen","year":"2025","journal-title":"RMD Open"},{"key":"10.1016\/j.coi.2026.102774_sbref55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib56","article-title":"The role of immunometabolism in the pathogenesis of systemic lupus erythematosus","volume":"12","author":"Robinson","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2026.102774_bib57","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2665-9913(24)00246-7","article-title":"Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"7","author":"Askanase","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.coi.2026.102774_bib58","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard-2022-222501","article-title":"Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial","volume":"81","author":"Humrich","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib59","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/annrheumdis-2019-215396","article-title":"Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial","volume":"79","author":"He","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib60","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1136\/ard-2022-222858","article-title":"Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus","volume":"81","author":"van Vollenhoven","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib61","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keaf536","article-title":"Secukinumab in active lupus nephritis: results from phase III, randomised, placebo-controlled study (SELUNE) and open-label extension study","volume":"65","author":"Zhao","year":"2026","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2026.102774_bib62","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/ard-2022-223739","article-title":"Efficacy and safety of emapalumab in macrophage activation syndrome","volume":"82","author":"De Benedetti","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ard.2025.06.2132","article-title":"Differential molecular signatures in response to CD19-CAR T cell therapy compared with conventional pharmacotherapy in systemic lupus erythematosus","volume":"85","author":"Garantziotis","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_bib64","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1136\/ard-2023-225445","article-title":"Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials","volume":"83","author":"Baker","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2026.102774_sbref65","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2026.102774_bib66","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1177\/0961203313515763","article-title":"A surge in anti-dsDNA titer predicts a severe lupus flare within six months","volume":"23","author":"Pan","year":"2014","journal-title":"Lupus"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000518?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791526000518?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T04:23:59Z","timestamp":1779510239000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791526000518"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"alternative-id":["S0952791526000518"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2026.102774","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New developments and future directions in the management of systemic lupus erythematosus","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2026.102774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102774"}}